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Conclusions: HSA is a useful method for detecting 
uncorrectable dose deviations derived from a clear clinical 
motivation. As such, it is a promising method for detecting 
deviations relevant to real-time dosimetry. However, the 
current number of false alerts is still too high for direct 
clinical implementation.  
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Purpose/Objective: Entrance dose in vivo dosimetry (IVD) 
using diodes is an end-to-end QA procedure that is widely 
used in conventional radiotherapy treatments. However, in 
advanced delivery techniques, such as SIB-IMRT, the 
reliability of this QA procedure is controversial. We 
developed a reliable QA procedure for breast treatments 
delivered using a SIB-IMRT technique based on IVD using 
diodes. 
Materials and Methods: We calibrated 6-12 MV QED diodes 
(Sun Nuclear) using an emX electrometer (IBA) in terms of 
entrance dose at SSD = 90 cm and field size = 10 cm x 20 cm 
(average conditions for IMRT breast treatments). We 
measured correction factors for distance, field size, 
obliquity, and MLC transmission. We planned 14 SIB breast 
treatments using 6MV x-rays and 7-9 sliding window IMRT 
fields (TPS: Eclipse, algorithm: AAA v8.9; Varian). 
Determining entrance dose points is challenging due to 
fluence modulation, and also to patient contour 
irregularities, beam obliquity and tissue heterogeneities. To 
minimize these challenges, we calculated all treatment fields 
at 0º gantry angle, maintaining the SSD, on a regular water 
phantom. For each field, we recorded entrance dose (at 
maximum dose depth) at two points: on the central axis and 
on the region of highest fluence. Treatments were performed 
using a Clinac 2100C/D equipped with a Millenium 120 MLC 
and the RPM system (Varian) for respiratory motion 
management. We placed one diode at each of the 
aforementioned points on the patients' skin. We assessed 
clinical uncertainties by placing the diodes at the same 
position but on a Plastic Water phantom (CIRS), and 
irradiating them under the conditions used for entrance dose 
calculations. To ensure positioning accuracy was lower than 
0.5 cm, we attached a template which projected a 1 cm 
square grid at isocenter to the collimator using an add-on. 
We compared IVD measurements with the calculated 
entrance doses. 
Results: The table shows the average difference between 
measurements and calculations, excluding doses below fixed 
thresholds. Consistency improved by increasing the threshold 
because we excluded false positives due to non-significant 
dose contributions. Although agreement between in-phantom 
measurements and calculations was excellent, in patients we 
observed larger differences and variability due to positioning 
inaccuracies (figure). The table shows the two-fold 
tolerances which provided >95% of acceptable IVD 
assessments. 
 
 
 
 
Conclusions: IVD using diodes is a feasible QA procedure for 
breast treatments delivered using a SIB-IMRT technique. We 
propose using two diodes per field in high-fluence regions 
(entrance dose >0.2 Gy). We suggest a two-fold tolerance for 
IVD assessment (95% confidence limits): a dose difference of 
15% for both diodes per field, and an average difference of 
3.6% including all measurements per patient. 
This work was funded by grant Barcelona Board of the 
Spanish Association Against Cancer (AECC) 2012. 
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Purpose/Objective: A co-ordinated research project (CRP) is 
under development and implementation within a 
collaborative multi-centre effort. The aim of the CRP is to 
broaden the portfolio of dosimetry audits offered to 
radiotherapy centres by national audit networks operating in 
middle and low income countries. Moreover, the inclusion of 
